| Velcera is a specialty pharmaceutical company focused on innovation in the expanding pet health market. Velcera's product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. Velcera's patented Promist™ drug delivery technology has the potential to increase compliance and improve pet health as owners avoid the challenges in getting pets to swallow pills.
June 30, 2008
Velcera Announces FDA Confirms VEL504 Clinical Program
June 19, 2008
Velcera Appoints Sal Uglietta to Board of Directors
June 9, 2008
Velcera Announces Completion of Enrollment in VEL502 Clinical Trial
June 2, 2008
Velcera Announces Positive FDA Meeting on VEL504 Product
April 24, 2008
Velcera Announces Initiation of Clinical Trial with VEL502
January 29 , 2008
Velcera Announces Results from Two Canine Allergy Studies
November 15, 2007
Velcera Receives FDA Feedback on Innovative Canine Allergy Product
November 5, 2007
Velcera to Present at 9th Annual Acumen BioFin Healthcare Conference
November 2, 2007
Velcera Shares Commence Trading
| 
